Resources

Barrett’s esophagus learning center

Chronic reflux in the esophagus causes changes to the molecular and cellular features of the esophagus, which often results in a condition called Barrett’s esophagus. Barrett’s is a serious complication of GERD and a known risk factor for the development of esophageal cancer. Learn more about risk factors, histology, diagnosis, treatment and cancer risk.

Graphic of where the Esophagus connects to the stomach

Scientific evidence

  • The tissue systems pathology test objectively risk-stratifies patients with Barrett’s esophagus results from a multicenter US clinical experience study

    01 Jul 2024

    This study highlights the clinical experience of TissueCypher testing ordered by 891 physicians in over 8,000 patients. This real-world clinical use of TissueCypher reflects the U.S. BE surveillance population with a significant proportion (93.9%) of diagnosed cases having NDBE and 94.3% of orders originating from community-based practices

    Villa NA, Ordonez-Castellanos M, Yodice M, et al.

  • A randomized controlled study on clinical adherence to evidence-based guidelines in the management of simulated patients with Barrett’s esophagus and the clinical utility of a tissue systems pathology test: results from Q-TAB

    12 Jan 2024

    TissueCypher optimized adherence to clinical guidelines for surveillance and treatment of both BE patients at high and low risk for disease progression. Use of the test can enable physicians to make risk-aligned management decisions, leading to improved patient health outcomes.  

    Peabody JW, et al.

  • An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients with Barrett's Esophagus

    01 Nov 2023

    Management guided by the TissueCypher test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.

    Duits, Lucas C, et al.

  • A Tissue Systems Pathology Test Outperforms the Standard of Care Variables in Predicting Progression in Patients with Barrett’s Esophagus

    01 Nov 2023

    This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.

    Davison JM, et al.

  • The Tissue Systems Pathology Test Outperforms Pathology Review in Risk-Stratifying Patients with Low-Grade Dysplasia

    01 Nov 2023

    This study aimed to compare the risk stratification performance of the TissueCypher test vs benchmarks of generalist and expert pathology.

    Khoshiwal AM, et al.